HYDERABAD: Dr Reddys Laboratories Ltd and the Russian Direct Investment Fund (RDIF) on Tuesday announced commencement of adaptive phase 2/3 clinical trials for COVID-19 vaccine Sputnik V in India after receiving necessary clearance from the Central Drugs Laboratory, Kasauli in Himachal Pradesh.
The Indian drug maker, in a release, said this will be a multicenter and randomized controlled study, which will include safety and immunogenicity study.
The clinical trials are being conducted by JSS Medical Research as the clinical research partner. (AGENCIES)
Follow our WhatsApp channel
